Korean Circulation Journal

  • 제42권8호
  • /
  • Pages.571-574
  • /
  • 2012
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Cardiac Sarcoidosis Presenting With Complete Atrioventricular Block and Sustained Monomorphic Ventricular Tachycardia

  • Lee, Joo-Myung (Cardiovascular Center and Department of Internal Medicine, Seoul National University Hospital) ;
  • Oh, Il-Young (Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital) ;
  • Choi, Dong-Ju (Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital)
  • 발행 : 2012.08.31
⟨ 이전 논문 다음 논문 ⟩

초록

Sarcoidosis is a rare but potentially fatal multisystem granulomatous disease of unknown etiology. While a number of clinical manifestations may develop, cardiac involvement (prior to or coincident with sarcoidosis of other organs) is an important prognostic factor. Recently, we encountered a patient with cardiac sarcoidosis who presented with complete atrioventricular (AV) block and sustained ventricular tachycardia. An implantable cardioverter-defibrillator was inserted as a precautionary measure for ventricular tachycardia and symp-tomatic complete AV block. $^{18}F$-fluoro-2-deoxyglucose positron emission tomography confirmed a dramatic response to high-dose steroid at four weeks, as demonstrated by a marked decrease in cardiac sarcoid activity from baseline status.

키워드

참고문헌

  1. Hagemann GJ WK. The clinical, electrocardiographic and pathological features of cardiac sarcoid. In: Jones Williams W, Davies BH, editors. Sarcoidosis and Other Granulomatous Disorders: Proceedings of the 8th International Conference Cardiff. Cardiff: Alpha & Omega Press; 1980. p.601-6.
  2. Johns CJ, Michele TM. The clinical management of sarcoidosis: a 50- year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999;78:65-111. https://doi.org/10.1097/00005792-199903000-00001
  3. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart: a clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977;63:86-108. https://doi.org/10.1016/0002-9343(77)90121-8
  4. Hiraga H, Yuwai K, Hiroe M. Guidelines for the Diagnosis of Cardiac Sarcoidosis: Study Report of Diffuse Pulmonary Diseases. Tokyo: Japanese Ministry of Health and Welfare;1993. p.23-4.
  5. Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 2004;83:315-34. https://doi.org/10.1097/01.md.0000145367.17934.75
  6. Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis: a 15-year European study. Am Rev Respir Dis 1984;130: 29-32.
  7. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234-41. https://doi.org/10.1093/oxfordjournals.aje.a009096
  8. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11. https://doi.org/10.1161/01.CIR.58.6.1204
  9. Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci 1976;278:455-69. https://doi.org/10.1111/j.1749-6632.1976.tb47058.x
  10. Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 1991;18:937-43. https://doi.org/10.1016/0735-1097(91)90750-4
  11. Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPAenhanced magnetic resonance imaging. Am J Med 2001;110: 520-7. https://doi.org/10.1016/S0002-9343(01)00677-5
  12. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 2002;122:1895-901. https://doi.org/10.1378/chest.122.6.1895
  13. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999;138(2 Pt 1):299-302. https://doi.org/10.1016/S0002-8703(99)70115-8
  14. Ohira H, Tsujino I, Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2011;38:1773-83. https://doi.org/10.1007/s00259-011-1832-y
  15. Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008;35:1537-43. https://doi.org/10.1007/s00259-008-0770-9
  16. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009;157:9-21. https://doi.org/10.1016/j.ahj.2008.09.009
  17. Reuhl J, Schneider M, Sievert H, Lutz FU, Zieger G. Myocardial sarcoidosis as a rare cause of sudden cardiac death. Forensic Sci Int 1997;89: 145-53 https://doi.org/10.1016/S0379-0738(97)00106-0
  18. Takada K, Ina Y, Yamamoto M, Satoh T, Morishita M. Prognosis after pacemaker implantation in cardiac sarcoidosis in Japan: clinical evaluation of corticosteroid therapy. Sarcoidosis 1994;11:113-7.
  19. Belhassen B, Pines A, Laniado S. Failure of corticosteroid therapy to prevent induction of ventricular tachycardia in sarcoidosis. Chest 1989; 95:918-20. https://doi.org/10.1378/chest.95.4.918